Influence of antiviral therapy in the long-term outcome of recurrent hepatitis C virus infection following liver transplantation

Transplant Infectious Disease

Volumn 15, Issue 4, 2013, Pages 405-415

  Garcia Reyne A ^a   Lumbreras, C ^a   Fernandez I ^a   Colina, F ^a   Abradelo, M ^a   Magan, P ^a   San Juan, R ^a   Manrique, A ^a   Lopez Medrano F ^a   Fuertes, A ^a   Lizasoain, M ^a   Moreno, E ^a   Aguado, J M ^a  

^a Universidad Complutense   (Spain)

Author keywords

Antiviral treatment; HCV; Hepatitis C; Risk factors; Transplant

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PEGINTERFERON; PEGINTERFERON ALPHA2B; RAPAMYCIN; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; STEROID; TACROLIMUS;

ADULT; AGE; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DONOR; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECIPIENT; RECURRENT DISEASE; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL; TREATMENT OUTCOME; VIRUS LOAD;

EID: 84880819571     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12097     Document Type: Article

References (41)

1. Chan SE, Rosen HR. Outcome and management of hepatitis C in liver transplant recipients. Clin Infect Dis 2003; 37 (6): 807-812.
2. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138 (2): 513-521.
3. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357 (25): 2601-2614.
4. Wiesner RH, Sorrell M, Villamil F. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9 (11): S1-S9.
5. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008; 14 (Suppl 2): S36-S44.
6. Berenguer M. Management of hepatitis C virus in the transplant patient. Clin Liver Dis 2007; 11 (2): 355-376.
7. Berenguer M, Prieto M, Rayon JM, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32 (4 Pt 1): 852-858.
8. Burak KW, Kremers WK, Batts KP, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002; 8 (4): 362-369.
9. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28 (3): 823-830.
10. Gallegos-Orozco JF, Yosephy A, Noble B, et al. Natural history of post-liver transplantation hepatitis C: a review of factors that may influence its course. Liver Transpl 2009; 15 (12): 1872-1881.
11. Lumbreras C, Colina F, Loinaz C, et al. Clinical, virological, and histologic evolution of hepatitis C virus infection in liver transplant recipients. Clin Infect Dis 1998; 26 (1): 48-55.
12. Veillon P, Payan C, Picchio G, Maniez-Montreuil M, Guntz P, Lunel F. Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy. J Clin Microbiol 2003; 41 (7): 3212-3220.
13. Scheuer PJ Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13 (3): 372-374.
14. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25 (3): 658-663.
15. Demetris AJ, Seaberg EC, Batts KP, et al. Reliability and predictive value of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database nomenclature and grading system for cellular rejection of liver allografts. Hepatology 1995; 21 (2): 408-416.
16. Demetris A, Adams D, Bellamy C, et al. Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology 2000; 31 (3): 792-799.
17. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34 (8): 1094-1107.
18. Ghobrial RM, Steadman R, Gornbein J, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 2001; 234 (3): 384-393; discussion 93-94.
19. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36 (1): 202-210.
20. Selzner N, Girgrah N, Lilly L, et al. The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age. Liver Transpl 2008; 14 (12): 1778-1786.
21. Alonso O, Loinaz C, Moreno E, et al. Advanced donor age increases the risk of severe recurrent hepatitis C after liver transplantation. Transpl Int 2005; 18 (8): 902-907.
22. Boin IF, Ataide EC, Leonardi MI, et al. Elderly donors for HCV (+) versus non-HCV recipients: patient survival following liver transplantation. Transplant Proc 2008; 40 (3): 792-796.
23. Lake JR, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Wiesner RH. Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. Am J Transplant 2005; 5 (3): 549-557.
24. Paradis V, Youssef N, Dargere D, et al. Replicative senescence in normal liver, chronic hepatitis C, and hepatocellular carcinomas. Hum Pathol 2001; 32 (3): 327-332.
25. Tillmann HL, Manns MP, Rudolph KL. Merging models of hepatitis C virus pathogenesis. Semin Liver Dis 2005; 25 (1): 84-92.
26. Sekoguchi S, Nakajima T, Moriguchi M, et al. Role of cell-cycle turnover and oxidative stress in telomere shortening and cellular senescence in patients with chronic hepatitis C. J Gastroenterol Hepatol 2007; 22 (2): 182-190.
27. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000; 32 (5): 1125-1130.
28. Everson GT, Terrault NA, Lok AS, et al.; Adult-to-Adult Living Donor Liver Transplantation Study. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology 2013; 57 (5): 1752-1762. Epub 23 July 2012.
29. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8 (4): 350-355.
30. Forns X, Garcia-Retortillo M, Serrano T, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003; 39 (3): 389-396.
31. Cameron AM, Ghobrial RM, Hiatt JR, et al. Effect of nonviral factors on hepatitis C recurrence after liver transplantation. Ann Surg 2006; 244 (4): 563-571.
32. Razonable RR, Burak KW, Van Cruijsen H, et al. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis 2002; 35 (8): 974-981.
33. Rosen HR, Chou S, Corless CL, et al. Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 1997; 64 (5): 721-726.
34. Nebbia G, Mattes FM, Cholongitas E, et al. Exploring the bidirectional interactions between human cytomegalovirus and hepatitis C virus replication after liver transplantation. Liver Transpl 2007; 13 (1): 130-135.
35. Teixeira R, Pastacaldi S, Davies S, et al. The influence of cytomegalovirus viraemia on the outcome of recurrent hepatitis C after liver transplantation. Transplantation 2000; 70 (10): 1454-1458.
36. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49 (2): 274-287.
37. Fernandez I, Meneu JC, Colina F, et al. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl 2006; 12 (12): 1805-1812.
38. Oton E, Barcena R, Moreno-Planas JM, et al. Hepatitis C recurrence after liver transplantation: viral and histologic response to full-dose PEG-interferon and ribavirin. Am J Transplant 2006; 6 (10): 2348-2355.
39. Berenguer M, Aguilera V, Prieto M, et al. Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. Liver Transpl 2009; 15 (7): 738-746.
40. Fukuhara T, Taketomi A, Motomura T, et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139 (5): 1577-1585.
41. Feray C, Gigou M, Samuel D, et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995; 108 (4): 1088-1096.